Stockreport

Pharvaris to Present Clinical Data at the AAAAI 2026 Annual Meeting

Pharvaris N.V. - Ordinary Shares  (PHVS) 
PDF ZUG, Switzerland, Feb. 10, 2026 (GLOBE NEWSWIRE) -- Pharvaris (Nasdaq: PHVS), a late-stage biopharmaceutical company developing novel, oral bradykinin B2 receptor anta [Read more]